447 related articles for article (PubMed ID: 32794589)
1. PCSK2 expression in neuroendocrine tumors points to a midgut, pulmonary, or pheochromocytoma-paraganglioma origin.
Remes SM; Leijon H; Vesterinen T; Louhimo J; Pulkkinen V; Ezer S; Kere J; Haglund C; Arola J
APMIS; 2020 Nov; 128(11):563-572. PubMed ID: 32794589
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin.
Lin X; Saad RS; Luckasevic TM; Silverman JF; Liu Y
Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):407-14. PubMed ID: 18091383
[TBL] [Abstract][Full Text] [Related]
3. ASO Author Reflections: Informing Patients About New Genetic Testing.
Romero Arenas MA; Grubbs EG
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):559-560. PubMed ID: 30617867
[No Abstract] [Full Text] [Related]
4. Neuroendocrine secretory protein-55 (NESP-55) expression discriminates pancreatic endocrine tumors and pheochromocytomas from gastrointestinal and pulmonary carcinoids.
Srivastava A; Padilla O; Fischer-Colbrie R; Tischler AS; Dayal Y
Am J Surg Pathol; 2004 Oct; 28(10):1371-8. PubMed ID: 15371954
[TBL] [Abstract][Full Text] [Related]
5. Challenges in Paragangliomas and Pheochromocytomas: from Histology to Molecular Immunohistochemistry.
Juhlin CC
Endocr Pathol; 2021 Jun; 32(2):228-244. PubMed ID: 33768452
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors.
Kimura N; Pilichowska M; Date F; Kimura I; Schindler M
Clin Cancer Res; 1999 Nov; 5(11):3483-7. PubMed ID: 10589762
[TBL] [Abstract][Full Text] [Related]
7. Retrospective application of the pathologic tumor-node-metastasis classification system for pheochromocytoma and abdominal paraganglioma in a well characterized cohort with long-term follow-up.
Stenman A; Zedenius J; Juhlin CC
Surgery; 2019 Nov; 166(5):901-906. PubMed ID: 31239074
[TBL] [Abstract][Full Text] [Related]
8. Expression of transforming growth factor alpha and its receptor in human neuroendocrine tumours.
Nilsson O; Wängberg B; Kölby L; Schultz GS; Ahlman H
Int J Cancer; 1995 Mar; 60(5):645-51. PubMed ID: 7860139
[TBL] [Abstract][Full Text] [Related]
9. Genetics, diagnosis, and management of medullary thyroid carcinoma and pheochromocytoma/paraganglioma.
Moraitis AG; Martucci VL; Pacak K
Endocr Pract; 2014 Feb; 20(2):176-87. PubMed ID: 24449662
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the utility of Cocaine- and Amphetamine-Regulated Transcript (CART), chromogranin A, and chromogranin B in neuroendocrine tumor diagnosis and assessment of disease progression.
Ramachandran R; Bech P; Murphy KG; Caplin ME; Patel M; Vohra S; Khan MS; Dhillo WS; Sharma R; Palazzo FF; Win Z; Tan T; Khoo B; Meeran K; Frilling A; Ghatei MA; Bloom SR; Martin NM
J Clin Endocrinol Metab; 2015 Apr; 100(4):1520-8. PubMed ID: 25664601
[TBL] [Abstract][Full Text] [Related]
11. Pitx2 is a useful marker of midgut-derived neuroendocrine tumours - an immunohistochemical study of 224 cases.
Soukup J; Manethova M; Faistova H; Krbal L; Vitovcova B; Hornychova H; Drugda J; Cesak T; Netuka D; Gabalec F; Ryska A
Histopathology; 2022 Dec; 81(6):799-807. PubMed ID: 36089904
[TBL] [Abstract][Full Text] [Related]
12. Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours.
Mohanty SK; Tiwari A; Bhardwaj N; Chuang F; Kim E; Lugo H; Yuan X; Diffalha SA; Peralta-Venturina M; Balzer B; Dhall D
J Clin Pathol; 2021 Sep; 74(9):582-588. PubMed ID: 32934105
[TBL] [Abstract][Full Text] [Related]
13. Long Non-coding RNAs in Pulmonary Neuroendocrine Neoplasms.
Narayanan D; Mandal R; Hardin H; Chanana V; Schwalbe M; Rosenbaum J; Buehler D; Lloyd RV
Endocr Pathol; 2020 Sep; 31(3):254-263. PubMed ID: 32388776
[TBL] [Abstract][Full Text] [Related]
14. Update on the management of unusual neuroendocrine tumors: pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma.
Strosberg JR
Semin Oncol; 2013 Feb; 40(1):120-33. PubMed ID: 23391119
[TBL] [Abstract][Full Text] [Related]
15. Long intergenic noncoding RNA profiles of pheochromocytoma and paraganglioma: A novel prognostic biomarker.
Ghosal S; Das S; Pang Y; Gonzales MK; Huynh TT; Yang Y; Taieb D; Crona J; Shankavaram UT; Pacak K
Int J Cancer; 2020 Apr; 146(8):2326-2335. PubMed ID: 31469413
[TBL] [Abstract][Full Text] [Related]
16. Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.
Guo Z; Lloyd RV
Adv Anat Pathol; 2015 Sep; 22(5):283-93. PubMed ID: 26262510
[TBL] [Abstract][Full Text] [Related]
17. Mastermind Like Transcriptional Coactivator 3 (MAML3) Drives Neuroendocrine Tumor Progression.
Alzofon N; Koc K; Panwell K; Pozdeyev N; Marshall CB; Albuja-Cruz M; Raeburn CD; Nathanson KL; Cohen DL; Wierman ME; Kiseljak-Vassiliades K; Fishbein L
Mol Cancer Res; 2021 Sep; 19(9):1476-1485. PubMed ID: 33986121
[TBL] [Abstract][Full Text] [Related]
18. Hereditary Neuroendocrine Tumors: Providing Comprehensive Care for Individuals Who Have a Germline Pathogenic Variant Associated With Paragangliomas and Pheochromocytomas.
Mahon SM
Clin J Oncol Nurs; 2021 Apr; 25(2):137-141. PubMed ID: 33739340
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical analysis of OTP and NKX6.1 in neuroendocrine tumors of the lung and pancreas.
Yoxtheimer LM; Heymann JJ; Cohen C; Rao RA; Goyal A; Siddiqui MT
Diagn Cytopathol; 2018 Dec; 46(12):1010-1014. PubMed ID: 30284410
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical distinction of paragangliomas from epithelial neuroendocrine tumors-gangliocytic duodenal and cauda equina paragangliomas align with epithelial neuroendocrine tumors.
Mamilla D; Manukyan I; Fetsch PA; Pacak K; Miettinen M
Hum Pathol; 2020 Sep; 103():72-82. PubMed ID: 32668278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
